American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

Ruggiero, 2009, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 Update, J Oral Maxillofac Surg, 67, 2

Nussbaum, 1993, Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages, Am J Med, 95, 297, 10.1016/0002-9343(93)90282-T

Major, 2001, Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials, J Clin Oncol, 19, 558, 10.1200/JCO.2001.19.2.558

Hortobagyi, 1996, Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group, N Engl J Med, 335, 1785, 10.1056/NEJM199612123352401

Hortobagyi, 1998, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group, J Clin Oncol, 16, 2038, 10.1200/JCO.1998.16.6.2038

Hillner, 2003, American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer, J Clin Oncol, 21, 4042, 10.1200/JCO.2003.08.017

Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458

Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141

Rosen, 2004, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial, Cancer, 100, 2613, 10.1002/cncr.20308

Berenson, 1996, Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group, N Engl J Med, 334, 488, 10.1056/NEJM199602223340802

Berenson, 1998, Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group, J Clin Oncol, 16, 593, 10.1200/JCO.1998.16.2.593

Rosen, 2001, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial, Cancer J, 7, 377

Berenson, 2002, American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma, J Clin Oncol, 20, 3719, 10.1200/JCO.2002.06.037

United States Food and Drug Administration, Center for Drug Evaluation and Research: Drugs @ FDA. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?CFID=22255647&CFTOKEN=bbf41c75f8cb0109-1F350AA8-A3B1-DF88-62056BCE97C69DB1. Accessed February 10, 2014

2003

Delmas, 1997, The management of Paget's disease of bone, N Engl J Med, 336, 558, 10.1056/NEJM199702203360807

Letocha, 2005, Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement, J Bone Miner Res, 20, 977, 10.1359/JBMR.050109

Watts, 2003, Bisphosphonate treatment of osteoporosis, Clin Geriatr Med, 19, 395, 10.1016/S0749-0690(02)00069-1

Delmas, 2005, The use of bisphosphonates in the treatment of osteoporosis, Curr Opin Rheumatol, 17, 462

Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493

Papapoulos, 2012, Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension, J Bone Miner Res, 27, 694, 10.1002/jbmr.1479

Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6

Stopeck, 2009, Denosumab versus zolendronic acid for the treatment of breast cancer patients with bone metastases: Results of a randomized phase 3 study, Eur J Cancer, 7, 2, 10.1016/S1359-6349(09)72028-2

Marx, 2003, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic, J Oral Maxillofac Surg, 61, 1115, 10.1016/S0278-2391(03)00720-1

Ruggiero, 2004, Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg, 62, 527, 10.1016/j.joms.2004.02.004

Hohnecker, 2004, 2

United States Food and Drug Administration, Oncologic Drugs Advisory Committee: Combidex briefing information. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B1_01_01-AdvancedMag-Combidex.pdf. Accessed February 10, 2014

United States Food and Drug Administration, Office of Drug Safety: Postmarketing safety review. Bisphosphonates. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_03_04-FDA-Tab3.pdf. Accessed February 10, 2014

Reid, 2007, Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?, Bone, 41, 318, 10.1016/j.bone.2007.04.196

Allen, 2009, The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data, J Oral Maxillofac Surg, 67, 61, 10.1016/j.joms.2009.01.007

Landesberg, 2011, Potential pathophysiological mechanisms in osteonecrosis of the jaw, Ann N Y Acad Sci, 1218, 62, 10.1111/j.1749-6632.2010.05835.x

Yamashita, 2012, Antiresorptives and osteonecrosis of the jaw, J Evid Based Dent Pract, 12, 233, 10.1016/S1532-3382(12)70046-5

Bamias, 2005, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors, J Clin Oncol, 23, 8580, 10.1200/JCO.2005.02.8670

Bi, 2010, Bisphosphonates cause osteonecrosis of the jaw-like disease in mice, Am J Pathol, 177, 280, 10.2353/ajpath.2010.090592

Hokugo, 2010, Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats, J Bone Miner Res, 25, 1337, 10.1002/jbmr.23

Mortensen, 2007, Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review, Laryngoscope, 117, 30, 10.1097/01.mlg.0000240885.64568.9e

Sonis, 2009, Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients, Oral Oncol, 45, 164, 10.1016/j.oraloncology.2008.04.013

Mehrotra, 2006, Bisphosphonate complications including osteonecrosis of the jaw, Hematology Am Soc Hematol Educ Program, 356, 10.1182/asheducation-2006.1.356

Ruggiero, 2006, Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102, 433, 10.1016/j.tripleo.2006.06.004

Wood, 2002, Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid, J Pharmacol Exp Ther, 302, 1055, 10.1124/jpet.102.035295

Baron, 2011, Denosumab and bisphosphonates: Different mechanisms of action and effects, Bone, 48, 677, 10.1016/j.bone.2010.11.020

Lacey, 2012, Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab, Nat Rev Drug Discov, 11, 401, 10.1038/nrd3705

Russell, 2008, Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy, Osteoporos Int, 19, 733, 10.1007/s00198-007-0540-8

Roelofs, 2006, Molecular mechanisms of action of bisphosphonates: Current status, Clin Cancer Res, 12, 6222s, 10.1158/1078-0432.CCR-06-0843

Russell, 1999, Bisphosphonates: From the laboratory to the clinic and back again, Bone, 25, 97, 10.1016/S8756-3282(99)00116-7

Aghaloo, 2011, Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat, J Bone Miner Res, 26, 1871, 10.1002/jbmr.379

Allen, 2008, Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment, J Oral Maxillofac Surg, 66, 987, 10.1016/j.joms.2008.01.038

Lipton, 2012, Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials, Eur J Cancer, 48, 3082, 10.1016/j.ejca.2012.08.002

Sinningen, 2012, Skeletal and extraskeletal actions of denosumab, Endocrine, 42, 52, 10.1007/s12020-012-9696-x

Aghaloo, 2010, Osteonecrosis of the jaw in a patient on denosumab, J Oral Maxillofac Surg, 68, 959, 10.1016/j.joms.2009.10.010

Kuroshima, 2013, Intra-oral PTH administration promotes tooth extraction socket healing, J Dent Res, 92, 553, 10.1177/0022034513487558

Dayisoylu, 2013, The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: An animal study, Int J Oral Maxillofac Surg, 42, 1475, 10.1016/j.ijom.2013.05.001

Dimopoulos, 2009, Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid, Ann Oncol, 20, 117, 10.1093/annonc/mdn554

Hoff, 2008, Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates, J Bone Miner Res, 23, 826, 10.1359/jbmr.080205

Ripamonti, 2009, Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Ann Oncol, 20, 137, 10.1093/annonc/mdn526

Boonyapakorn, 2008, Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies, Oral Oncol, 44, 857, 10.1016/j.oraloncology.2007.11.012

Marx, 2011

Marx, 2005, Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment, J Oral Maxillofac Surg, 63, 1567, 10.1016/j.joms.2005.07.010

Ficarra, 2005, Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment, J Clin Periodontol, 32, 1123, 10.1111/j.1600-051X.2005.00842.x

Aguirre, 2012, Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis, J Bone Miner Res, 27, 2130, 10.1002/jbmr.1669

Kang, 2013, Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice, J Bone Miner Res, 28, 1631, 10.1002/jbmr.1894

Mawardi, 2009, Sinus tracts—An early sign of bisphosphonate-associated osteonecrosis of the jaws?, J Oral Maxillofac Surg, 67, 593, 10.1016/j.joms.2008.09.031

Lopez-Jornet, 2011, Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: A study of the changes in the jaws, J Oral Maxillofac Surg, 69, 2488, 10.1016/j.joms.2011.02.059

Gotcher, 1981, The progress of the periodontal syndrome in the rice rat. I. Morphometric and autoradiographic studies, J Periodontal Res, 16, 275, 10.1111/j.1600-0765.1981.tb00976.x

Hansen, 2006, Osteonecrosis of the jaws in patients treated with bisphosphonates—Histomorphologic analysis in comparison with infected osteoradionecrosis, J Oral Pathol Med, 35, 155, 10.1111/j.1600-0714.2006.00391.x

Sedghizadeh, 2008, Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy, J Oral Maxillofac Surg, 66, 767, 10.1016/j.joms.2007.11.035

Kos, 2013, Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw?, J Oral Maxillofac Surg, 71, 1010, 10.1016/j.joms.2012.12.005

Sedghizadeh, 2009, Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy, J Am Dent Assoc, 140, 1259, 10.14219/jada.archive.2009.0049

Sedghizadeh, 2012, Metagenomic investigation of microbes and viruses in patients with jaw osteonecrosis associated with bisphosphonate therapy, Oral Surg Oral Med Oral Pathol Oral Radiol, 114, 764, 10.1016/j.oooo.2012.08.444

Wanger, 2013, Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms, Oral Surg Oral Med Oral Pathol Oral Radiol, 115, 71, 10.1016/j.oooo.2012.08.446

Kim, 2007, Introduction to osteonecrosis of the femoral head (OFH) and osteonecrosis of the jaw (ONJ), J Musculoskelet Neuronal Interact, 7, 350

Bezzi, 2003, Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt, J Biol Chem, 278, 43603, 10.1074/jbc.M308114200

Santini, 2003, Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients, Clin Cancer Res, 9, 2893

Lin, 1996, Bisphosphonates: A review of their pharmacokinetic properties, Bone, 18, 75, 10.1016/8756-3282(95)00445-9

Giraudo, 2004, An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis, J Clin Invest, 114, 623, 10.1172/JCI200422087

Montague, 2004, Differential inhibition of invasion and proliferation by bisphosphonates: Anti-metastatic potential of zoledronic acid in prostate cancer, Eur Urol, 46, 389, 10.1016/j.eururo.2004.04.022

Landesberg, 2008, Inhibition of oral mucosal cell wound healing by bisphosphonates, J Oral Maxillofac Surg, 66, 839, 10.1016/j.joms.2008.01.026

Reid, 2012, Epidemiology and pathogenesis of osteonecrosis of the jaw, Nat Rev Rheumatol, 8, 90, 10.1038/nrrheum.2011.181

Ali-Erdem, 2011, Extraction socket healing in rats treated with bisphosphonate: Animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients, Med Oral Patol Oral Cir Bucal, 16, e879, 10.4317/medoral.17150

Kikuiri, 2010, Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice, J Bone Miner Res, 25, 1668, 10.1002/jbmr.37

Qi, 2014, Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials, Int J Clin Oncol, 19, 403, 10.1007/s10147-013-0561-6

Coleman, 2011, Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer, Breast Cancer Res Treat, 127, 429, 10.1007/s10549-011-1429-y

Mauri, 2009, Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: A meta-analysis, Breast Cancer Res Treat, 116, 433, 10.1007/s10549-009-0432-z

Vahtsevanos, 2009, Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw, J Clin Oncol, 27, 5356, 10.1200/JCO.2009.21.9584

Scagliotti, 2012, Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study, J Thorac Oncol, 7, 1823, 10.1097/JTO.0b013e31826aec2b

Guarneri, 2010, Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer, Breast Cancer Res Treat, 122, 181, 10.1007/s10549-010-0866-3

Lo, 2010, Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure, J Oral Maxillofac Surg, 68, 243, 10.1016/j.joms.2009.03.050

Malden, 2012, An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence, J Bone Miner Metab, 30, 171, 10.1007/s00774-011-0299-z

Grbic, 2010, The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program, J Am Dent Assoc, 141, 1365, 10.14219/jada.archive.2010.0082

Henry, 2011, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, 29, 1125, 10.1200/JCO.2010.31.3304

Koch, 2011, Osteonecrosis of the jaw related to sunitinib, J Oral Maxillofac Surg, 15, 63, 10.1007/s10006-010-0224-y

Nicolatou-Galitis, 2012, Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications, Oral Surg Oral Med Oral Pathol Oral Radiol, 113, 234, 10.1016/j.tripleo.2011.08.024

Fleissig, 2012, Sunitinib related osteonecrosis of jaw: A case report, Oral Surg Oral Med Oral Pathol Oral Radiol, 113, e1, 10.1016/j.tripleo.2011.06.023

Brunello, 2009, Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma, Bone, 44, 173, 10.1016/j.bone.2008.08.132

Ayllon, 2009, Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: Cumulative toxicity profile?, Ann Oncol, 20, 600, 10.1093/annonc/mdn788

Christodoulou, 2009, Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone, Oncology, 76, 209, 10.1159/000201931

Balmor, 2012, Drug-induced palate osteonecrosis following nasal surgery, Isr Med Assoc J, 14, 193

Hoefert, 2010, Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of three cases, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 110, 463, 10.1016/j.tripleo.2010.04.049

Bozas, 2010, Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib, Onkologie, 33, 321, 10.1159/000313680

Beuselinck, 2012, Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases, Br J Cancer, 107, 1665, 10.1038/bjc.2012.385

Smidt-Hansen, 2013, Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma, J Oral Maxillofac Surg, 71, 1532, 10.1016/j.joms.2013.03.019

United States Food and Drug Administration: Avastin (bevacizumab) safety information. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm275758.htm. Accessed March 13, 2014

United States Food and Drug Administration: Sutent (sunitinib malate) capsules. Safety information. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/ucm224050.htm. Accessed March 13, 2014

United States Food and Drug Administration: Background document for meeting of advisory committee for reproductive health drugs and drug safety and risk management advisory committee. September 9, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm270958.pdf. Accessed February 10, 2014

Felsenberg, 2006, [Necrosis of the jaw after high-dose bisphosphonate therapy], Dtsch Arztebl, 103, 3078

Black, 2012, The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res, 27, 243, 10.1002/jbmr.1494

United States Food and Drug Administration: Briefing information for the September 9, 2011 joint meeting of the reproductive health drugs advisory committee and the drug safety and risk management advisory committee. September 9, 2011. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm270957.htm. Accessed April 7, 2014

Saad, 2012, Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases, Ann Oncol, 23, 1341, 10.1093/annonc/mdr435

Fehm, 2009, Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies, Gynecol Oncol, 112, 605, 10.1016/j.ygyno.2008.11.029

Kyrgidis, 2008, Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients, J Clin Oncol, 26, 4634, 10.1200/JCO.2008.16.2768

Kunchur, 2009, Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws, J Oral Maxillofac Surg, 67, 1167, 10.1016/j.joms.2009.02.004

Yamazaki, 2012, Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: A cohort study, Int J Oral Maxillofac Surg, 41, 1397, 10.1016/j.ijom.2012.06.020

Mozzati, 2012, Tooth extraction in patients on zoledronic acid therapy, Oral Oncol, 48, 817, 10.1016/j.oraloncology.2012.03.009

Scoletta, 2013, Tooth extractions in intravenous bisphosphonate-treated patients: A refined protocol, J Oral Maxillofac Surg, 71, 994, 10.1016/j.joms.2013.01.006

Tsao, 2013, Oral health risk factors for bisphosphonate-associated jaw osteonecrosis, J Oral Maxillofac Surg, 71, 1360, 10.1016/j.joms.2013.02.016

Brown, 2008, Bisphosphonate-associated osteonecrosis of the jaw: Does it occur in children?, Clin Endocrinol (Oxf), 68, 863, 10.1111/j.1365-2265.2008.03189.x

Katz, 2011, Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw, Int J Oral Maxillofac Surg, 40, 605, 10.1016/j.ijom.2011.02.002

Nicoletti, 2012, Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: The role of RBMS3, Oncologist, 17, 279, 10.1634/theoncologist.2011-0202

Marini, 2011, Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw, Front Biosci (Elite Ed), 3, 364, 10.2741/e251

Sivolella, 2013, Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: An uncommon but potentially severe disease, Anticancer Res, 33, 1793

Epstein, 2012, The effects of osteoclast modifiers on the oral cavity: A review for prescribers, Curr Opin Support Palliat Care, 6, 337, 10.1097/SPC.0b013e3283560646

Vescovi, 2012, Bisphosphonates-related osteonecrosis of the jaws: A concise review of the literature and a report of a single-centre experience with 151 patients, J Oral Pathol Med, 41, 214, 10.1111/j.1600-0714.2011.01091.x

Schubert, 2012, The Saxon bisphosphonate register—Therapy and prevention of bisphosphonate-related osteonecrosis of the jaws, Oral Oncol, 48, 349, 10.1016/j.oraloncology.2011.11.004

Shannon, 2011, Bisphosphonates and osteonecrosis of the jaw, J Am Geriatr Soc, 59, 2350, 10.1111/j.1532-5415.2011.03713.x

Lo, 2011, Oral health considerations in older women receiving oral bisphosphonate therapy, J Am Geriatr Soc, 59, 916, 10.1111/j.1532-5415.2011.03371.x

Hellstein, 2011, Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs, J Am Dent Assoc, 142, 1243, 10.14219/jada.archive.2011.0108

Patel, 2011, Bisphosphonate osteonecrosis of the jaw—A literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention, Br J Oral Maxillofac Surg, 49, 251, 10.1016/j.bjoms.2010.05.007

Atalay, 2011, Bisphosphonate-related osteonecrosis: Laser-assisted surgical treatment or conventional surgery?, Lasers Med Sci, 26, 815, 10.1007/s10103-011-0974-2

Aapro, 2010, Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases, Oncologist, 15, 1147, 10.1634/theoncologist.2007-0245

Fehm, 2009, Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: Recommendations for prevention and treatment, Breast, 18, 213, 10.1016/j.breast.2009.07.001

Walter, 2009, Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients, Cancer, 115, 1631, 10.1002/cncr.24119

Khan, 2009, Bisphosphonate associated osteonecrosis of the jaw, J Rheumatol, 36, 478, 10.3899/jrheum.080759

Dickinson, 2009, Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: An overview with recommendations for prevention and treatment, Intern Med J, 39, 304, 10.1111/j.1445-5994.2008.01824.x

Edwards, 2008, Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs, J Am Dent Assoc, 139, 1674, 10.14219/jada.archive.2008.0110

Abu-Id, 2008, “Bis-phossy jaws”—High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw, J Craniomaxillofac Surg, 36, 95, 10.1016/j.jcms.2007.06.008

Kyle, 2007, American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma, J Clin Oncol, 25, 2464, 10.1200/JCO.2007.12.1269

Bonacina, 2011, Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: A review of 282 patients, J Can Dent Assoc, 77, b147

Vandone, 2012, Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience, Ann Oncol, 23, 193, 10.1093/annonc/mdr039

Hinchy, 2013, Osteonecrosis of the jaw—Prevention and treatment strategies for oral health professionals, Oral Oncol, 49, 878, 10.1016/j.oraloncology.2013.06.008

Khan AA, Morrison A, Hanley DA, et al: International consensus on diagnosis and management of osteonecrosis of the jaw. J Bone Miner Res:22, 2013

Damm, 2013, Bisphosphonate-related osteonecrosis of the jaws: A potential alternative to drug holidays, Gen Dent, 61, 33

Durie, 2005, Osteonecrosis of the jaw and bisphosphonates, N Engl J Med, 353, 99, 10.1056/NEJM200507073530120

Hoff, 2006, Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy, J Clin Oncol, 24, 8528, 10.1200/jco.2006.24.18_suppl.8528

Badros, 2006, Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors, J Clin Oncol, 24, 945, 10.1200/JCO.2005.04.2465

Mehrotra, 2008, Outcomes of bisphosphonate related osteonecrosis of the jaw. Importance of staging and management. A large single institution update, J Clin Oncol, 26, 20526, 10.1200/jco.2008.26.15_suppl.20526

2010, 4

Marx, 2007, Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment, J Oral Maxillofac Surg, 65, 2397, 10.1016/j.joms.2007.08.003

Carlson, 2009, The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws, J Oral Maxillofac Surg, 67, 85, 10.1016/j.joms.2009.01.006

Bagan, 2008, Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates, Oral Oncol, 44, 1088, 10.1016/j.oraloncology.2008.01.012

Kwon, 2009, Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws, J Oral Maxillofac Surg, 67, 2644, 10.1016/j.joms.2009.04.067

Lehrer, 2008, Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 106, 389, 10.1016/j.tripleo.2008.01.033

Migliorati, 2013, Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction, J Am Dent Assoc, 144, 406, 10.14219/jada.archive.2013.0134

Fleisher, 2010, Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 110, 509, 10.1016/j.tripleo.2010.04.023

Rosen, 2000, Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy, Calcif Tissue Int, 66, 100, 10.1007/PL00005830

Kim, 2013, The effect of systemically administered bisphosphonates on bony healing after tooth extraction and osseointegration of dental implants in the rabbit maxilla, Int J Oral Maxillofac Implants, 28, 1194, 10.11607/jomi.2685

Graziani, 2012, Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: A retrospective survey of 347 cases, J Oral Maxillofac Surg, 70, 2501, 10.1016/j.joms.2012.05.019

Stanton, 2009, Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: Review of 33 surgical cases, J Oral Maxillofac Surg, 67, 943, 10.1016/j.joms.2008.12.057

Stockmann, 2010, Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: A prospective clinical study with 12 months follow-up, Support Care Cancer, 18, 449, 10.1007/s00520-009-0688-1

Mucke, 2011, Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws, J Cancer Res Clin Oncol, 137, 907, 10.1007/s00432-010-0953-1

Eckardt, 2011, Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients: A challenging problem, Anticancer Res, 31, 2313

Ferlito, 2012, Treatment of bisphosphonate-related osteonecrosis of the jaws: Presentation of a protocol and an observational longitudinal study of an Italian series of cases, Br J Oral Maxillofac Surg, 50, 425, 10.1016/j.bjoms.2011.08.004

Saussez, 2009, Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: A Belgian case series, Laryngoscope, 119, 323, 10.1002/lary.20076

Scoletta, 2010, Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: A prospective study, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 110, 46, 10.1016/j.tripleo.2010.02.020

Van den Wyngaert, 2009, Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome, Ann Oncol, 20, 331, 10.1093/annonc/mdn630

Wutzl, 2008, Treatment results of bisphosphonate-related osteonecrosis of the jaws, Head Neck, 30, 1224, 10.1002/hed.20864

Kademani, 2006, Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy, Mayo Clin Proc, 81, 1100, 10.4065/81.8.1100

Freiberger, 2012, What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: A randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics, J Oral Maxillofac Surg, 70, 1573, 10.1016/j.joms.2012.04.001

Freiberger, 2009, Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws, J Oral Maxillofac Surg, 67, 96, 10.1016/j.joms.2008.12.003

Lee, 2007, Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: A report of 2 cases, J Oral Implantol, 33, 371, 10.1563/1548-1336(2007)33[371:UOPPIT]2.0.CO;2

Soydan, 2014, Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: Technical report, J Oral Maxillofac Surg, 72, 322, 10.1016/j.joms.2013.07.027

Scoletta, 2010, Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: Preliminary results of a prospective study, Photomed Laser Surg, 28, 179, 10.1089/pho.2009.2501

Vescovi, 2008, Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: Clinical experience in 28 cases, Photomed Laser Surg, 26, 37, 10.1089/pho.2007.2181

Bashutski, 2010, Teriparatide and osseous regeneration in the oral cavity, N Engl J Med, 363, 2396, 10.1056/NEJMoa1005361

Gerard, 2014, Early inhibitory effects of zoledronic acid in tooth extraction sockets in dogs are negated by recombinant human bone morphogenetic protein, J Oral Maxillofac Surg, 72, 61, 10.1016/j.joms.2013.06.192

Fedele, 2010, Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series, Am J Med, 123, 1060, 10.1016/j.amjmed.2010.04.033

O'Ryan, 2009, Intravenous bisphosphonate-related osteonecrosis of the jaw: Bone scintigraphy as an early indicator, J Oral Maxillofac Surg, 67, 1363, 10.1016/j.joms.2009.03.005

Bedogni, 2012, Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ), Oral Dis, 18, 621, 10.1111/j.1601-0825.2012.01903.x

Schiodt, 2014, Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: A retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system, Oral Surg Oral Med Oral Pathol Oral Radiol, 117, 204, 10.1016/j.oooo.2013.10.010

Kumar, 2010, The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy, Curr Osteoporos Rep, 8, 40, 10.1007/s11914-010-0008-1

Engroff, 2007, Treating bisphosphonate osteonecrosis of the jaws: Is there a role for resection and vascularized reconstruction?, J Oral Maxillofac Surg, 65, 2374, 10.1016/j.joms.2006.07.012

Ferrari, 2008, Fibula free flap with endosseous implants for reconstructing a resected mandible in bisphosphonate osteonecrosis, J Oral Maxillofac Surg, 66, 999, 10.1016/j.joms.2007.06.631

Seth, 2010, Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws, Laryngoscope, 120, 2165, 10.1002/lary.21062

Carlson, 2013, Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications, J Oral Maxillofac Surg, 71, 2077, 10.1016/j.joms.2013.05.014

United States National Institutes of Health: Funding opportunities and notices search results. Available at: http://grants.nih.gov/grants/guide/search_results.htm?text_curr=osteonecrosis&scope=pa-rfa&year=active&sort=&Search.x=10&Search.y=8. Accessed February 10, 2014